INTRODUCTION: Prostate cancer is the most frequently diagnosed non-skin cancer in the United States and the third leading cause of cancer deaths. International trends in the incidence, mortality and prevalence of prostate cancer are assessed. METHODS: Databases from the Surveillance, Epidemiology and End Results (SEER) program of the National Cancer Institute and the International Agency for Research on Cancer (IARC), and the literature on autopsy studies on prostate cancer were reviewed and summarized in the article. RESULTS: Prostate cancer remains an important public health concern in Western countries and an emerging malignancy in developing nations. Prostate cancer incidence is dependent on efforts to detect the disease. Autopsy studies provide accurate and useful information regarding comparative prevalence rates of the disease among regions of interest. CONCLUSIONS: Improved cancer registration is needed in developing nations. The prevalence of prostate cancer must be established to predict the expected incidence of the disease and in order to plan rational detection and treatment strategies. Clinically significant disease should be distinguished from insignificant disease which may pose little or no biological danger to the patient.
INTRODUCTION:Prostate cancer is the most frequently diagnosed non-skin cancer in the United States and the third leading cause of cancer deaths. International trends in the incidence, mortality and prevalence of prostate cancer are assessed. METHODS: Databases from the Surveillance, Epidemiology and End Results (SEER) program of the National Cancer Institute and the International Agency for Research on Cancer (IARC), and the literature on autopsy studies on prostate cancer were reviewed and summarized in the article. RESULTS:Prostate cancer remains an important public health concern in Western countries and an emerging malignancy in developing nations. Prostate cancer incidence is dependent on efforts to detect the disease. Autopsy studies provide accurate and useful information regarding comparative prevalence rates of the disease among regions of interest. CONCLUSIONS: Improved cancer registration is needed in developing nations. The prevalence of prostate cancer must be established to predict the expected incidence of the disease and in order to plan rational detection and treatment strategies. Clinically significant disease should be distinguished from insignificant disease which may pose little or no biological danger to the patient.
Authors: N Breslow; C W Chan; G Dhom; R A Drury; L M Franks; B Gellei; Y S Lee; S Lundberg; B Sparke; N H Sternby; H Tulinius Journal: Int J Cancer Date: 1977-11-15 Impact factor: 7.396
Authors: Ruth Etzioni; David F Penson; Julie M Legler; Dante di Tommaso; Rob Boer; Peter H Gann; Eric J Feuer Journal: J Natl Cancer Inst Date: 2002-07-03 Impact factor: 13.506
Authors: Ching Y Wang; Richard F Jones; Maria Debiec-Rychter; Gyorgyike Soos; Gabriel P Haas Journal: Anticancer Res Date: 2002 Nov-Dec Impact factor: 2.480
Authors: Ian M Thompson; Phyllis J Goodman; Catherine M Tangen; M Scott Lucia; Gary J Miller; Leslie G Ford; Michael M Lieber; R Duane Cespedes; James N Atkins; Scott M Lippman; Susie M Carlin; Anne Ryan; Connie M Szczepanek; John J Crowley; Charles A Coltman Journal: N Engl J Med Date: 2003-06-24 Impact factor: 91.245
Authors: Ian M Thompson; Donna K Pauler; Phyllis J Goodman; Catherine M Tangen; M Scott Lucia; Howard L Parnes; Lori M Minasian; Leslie G Ford; Scott M Lippman; E David Crawford; John J Crowley; Charles A Coltman Journal: N Engl J Med Date: 2004-05-27 Impact factor: 91.245
Authors: Matthew R Cooperberg; Deborah P Lubeck; Maxwell V Meng; Shilpa S Mehta; Peter R Carroll Journal: J Clin Oncol Date: 2004-06-01 Impact factor: 44.544
Authors: A Cannistraci; G Federici; A Addario; A L Di Pace; L Grassi; G Muto; D Collura; M Signore; L De Salvo; S Sentinelli; G Simone; M Costantini; S Nanni; A Farsetti; V Coppola; R De Maria; D Bonci Journal: Oncogene Date: 2017-02-13 Impact factor: 9.867
Authors: H Wadhwa; M K Terris; W J Aronson; C J Kane; C L Amling; M R Cooperberg; S J Freedland; M R Abern Journal: Prostate Cancer Prostatic Dis Date: 2016-10-04 Impact factor: 5.554
Authors: Shivani Pahwa; Nicholas K Schiltz; Lee E Ponsky; Ziang Lu; Mark A Griswold; Vikas Gulani Journal: Radiology Date: 2017-05-17 Impact factor: 11.105
Authors: Rui Li; Sheng Xu; Ivane Bakhutashvili; Ismail B Turkbey; Peter Choyke; Peter Pinto; Bradford Wood; Zion T H Tse Journal: Ann Biomed Eng Date: 2018-11-28 Impact factor: 3.934